Taking that all the pre-clinical work was done, and the phase 1 trial already started prior to the IPO, I think the wait for CHM to bloom will be significantly shorter than the normal Biotech pathway. Plans already underway for the Phase 2b, which if successful will lead to drug approval. A quick google search of FDA CarT approved drugs will show there market value. It also shows how these drugs are getting accellerated approvals even with high adverse event rates.
I believe the first real readout from this phase 1 is due in the Sept quarter. Good news there will get the party started. Potential drug approval within 24 to 36 months from then. Very low SOI, large pivot events in a relatively short period of time all sound like opportunity to me. An excellent setup to support the science if it works as well with patients as it did in the lab.
Enough money in the bank to get this drug over the line. Lots to like about CHM.
CHM Price at posting:
28.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)